Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureChunyuan Gan, Jingheng Xiang, Shili Nie, Lian Yi, Yaqin Tang, 崔建国
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
10.1038/nrd4010 · 2013
Unraveling resistance mechanisms to the novel nucleoside analog RX-3117 in lung cancer: insights into DNA repair, cell cycle dysregulation and targeting PKMYT1 for improved therapy
10.1186/s13046-025-03470-z · 2025
AP1M2 Drives Gemcitabine‐Cisplatin Chemoresistance by Enhancing RAD54B‐Associated DNA Repair in Bladder Cancer
10.1096/fj.202500423r · 2025
Epigenetic Drivers of Chemoresistance in Nucleobase and Nucleoside Analog Therapies
10.3390/biology14070838 · 2025
Epigenetic Biomarkers for predicting Nucleoside Analog Drug Response and Resistance in Cancer
10.3390/biom16040587 · 2026
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
10.1038/s41392-023-01480-x · 2023
Exploring viral mimicry combined with epigenetics and tumor immunity: new perspectives in cancer therapy
10.7150/ijbs.103877 · 2025
Advanced prodrug strategies in nucleoside analogues targeting the treatment of gastrointestinal malignancies
10.3389/fcell.2023.1173432 · 2023
Advancing Epigenetic Combination Therapy in Oncology: Multifunctional Nano-Drug delivery Systems for Synergistic Efficacy and Precision Modulation
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
2025
The Role of SAMHD1 in Viral Resistance and Transduction Efficiency challenges in Pediatric Hematological Malignancies: Mechanistic Insights and Clinical Perspectives
2025
Unresolved referenced work
2025
Microbial metabolites in tumor metabolic reprogramming and immunotherapy: new insights
10.3389/fcimb.2025.1706040 · 2025
Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer
10.3389/fphar.2024.1510851 · 2025
Current and emerging prodrug strategies
10.1021/acs.jmedchem.5c00826 · 2025
Prodrug-based drug delivery systems: strategic approaches and emerging challenges in targeted therapeutics
2025
The ProTide Prodrug Technology: from the Concept to the Clinic: Miniperspective
10.1021/acs.jmedchem.7b00734 · 2017
Is monitoring of the intracellular active metabolite levels of nucleobase and nucleoside analogs ready for precision medicine applications?
10.1007/s13318-022-00786-5 · 2022
Cell and tissue specific metabolism of nucleoside and nucleotide drugs: case studies and implications for precision medicine
10.1124/dmd.122.000856 · 2023
Clinical translation of Self‐Assembled cancer nanomedicines
2021
Prodrug-based combinational nanomedicine remodels lipid metabolism for reinforced ferroptosis and immune activation
10.1016/j.apsb.2025.03.016 · 2025
Is it still worth renewing nucleoside anticancer drugs nowadays?
10.1016/j.ejmech.2023.115987 · 2024
A general nanoplatform for nucleotide drug delivery: from molecular binding to antiviral therapy
2025
Application of artificial intelligence in drug discovery
10.2174/1381612828666220608141049 · 2022
Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs
10.1021/acs.chemrev.6b00209 · 2016
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
10.1186/s13045-022-01263-x · 2022
Nucleoside-based anticancer drugs: Mechanism of action and drug resistance
10.1016/j.bcp.2023.115741 · 2023
Emerging roles of nucleotide metabolism in cancer
10.1016/j.trecan.2023.04.008 · 2023
Nucleosides with fluorinated nucleobases for antiviral and anticancer therapies
10.1016/j.fmre.2025.06.002 · 2025
Enhancing the Nucleoside Analog Response with Translational Therapeutic Approaches to Overcome Resistance
10.3390/cells15020130 · 2026
5-fluorouracil: mechanisms of action and clinical strategies
10.1038/nrc1074 · 2003
Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells
2009
APOBEC3 upregulation drives gemcitabine resistance
10.1038/s43018-024-00755-8 · 2024
A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability
10.1038/s41401-019-0227-7 · 2019
Unlocking the potential of cytarabine: a comprehensive review from molecular insights to advanced nanoformulations and Co-delivery strategies for enhanced drug efficacy
10.1016/j.jddst.2024.106346 · 2024
Gemcitabine alters phosphatidylcholine metabolism in mouse pancreatic tumors
10.1021/acs.jproteome.4c00839 · 2025
Recent progress in gemcitabine-loaded nanoparticles for pancreatic cancer therapy: a review
10.1039/d5nr02005k · 2025
Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK/T cell lymphoma cells
10.3389/fphar.2023.1134895 · 2023
Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer
10.1021/cr900028p · 2009
DNA replication stress induced by trifluridine determines tumor cell fate according to p53 status
10.1158/1541-7786.mcr-19-1051 · 2020
TAS-102, a novel antitumor agent: a review of the mechanism of action
10.1016/j.ctrv.2015.06.001 · 2015
Clinical application and drug resistance mechanism of gemcitabine
10.3389/fcell.2025.1702720 · doi-reference
Transfer learning with multiomics integration and deep neural networks reveals drug resistance mechanisms in cancer
10.1038/s41598-025-23435-8 · doi-reference
Transformer-based Molecular Generative Model for Antiviral Drug Design
10.1021/acs.jcim.3c00536 · doi-reference
Targeting PD‐L1 with DNA Aptamers and Conjugated with Gemcitabine as a Novel Therapeutic Strategy for Bladder Cancer Chemotherapy combined with Immunotherapy
10.1002/smsc.202370023 · doi-reference
Macrophage membrane-coated nano-gemcitabine promotes lymphocyte infiltration and synergizes AntiPD-L1 to restore the tumoricidal function
10.1021/acsnano.2c07861 · doi-reference
5-FU@ HFn combined with decitabine induces pyroptosis and enhances antitumor immunotherapy for chronic myeloid leukemia
10.1186/s12951-025-03335-9 · doi-reference
Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma
10.1186/s12943-020-01297-0 · doi-reference
A phase I/II trial of oral SRA737 (a Chk1 Inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer
10.1158/1078-0432.ccr-22-2074 · doi-reference
Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer
10.1016/j.biopha.2023.115389 · doi-reference
Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia
10.1186/s12935-023-03057-8 · doi-reference
Reverse intratumor bacteria-induced gemcitabine resistance with carbon nanozymes for enhanced tumor catalytic-chemo therapy
10.1016/j.nantod.2022.101395 · doi-reference
nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer
10.1158/2159-8290.cd-11-0242 · doi-reference
Barrier permeation and improved nanomedicine delivery in tumor microenvironments
10.1016/j.canlet.2023.216166 · doi-reference
Rational formulation and industrial manufacturing of lipid-based complex injectables: Landmarks and trends
10.1016/j.jconrel.2024.07.021 · doi-reference
FU-coating pH-sensitive liposomes for improving the release of gemcitabine by endosome escape in pancreatic cancer cells
10.1016/j.jddst.2022.104135 · doi-reference
Cascade‐Targeted Nanoparticles for Enhanced Gemcitabine delivery and Adenosine Metabolism Modulation to Overcome Treatment Resistance in Pancreatic Cancer
10.1002/advs.202507118 · doi-reference
Collagenase-functionalized liposomes overcome stromal barriers in pancreatic cancer
10.1021/acsnano.5c20618 · doi-reference
Nanoassemblies from amphiphilic cytarabine prodrug for leukemia targeted therapy
10.1016/j.jcis.2016.10.041 · doi-reference
A bioinspired supramolecular nanoprodrug for precision therapy of B-cell non-Hodgkin’s lymphoma
10.1186/s12951-024-02745-5 · doi-reference
Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis
10.1016/j.apsb.2023.03.004 · doi-reference
Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation
10.1186/s12943-025-02325-7 · doi-reference
Gemcitabine and Pin1 siRNA co-delivery with fucoidan-coated nano-liposomes for therapy of pancreatic cancer
10.1016/j.jddst.2023.104872 · doi-reference
Orally delivered berberine derivatives for dual therapy in diabetic complications with MRSA infections
10.1016/j.cclet.2024.109917 · doi-reference
Self-assembled lipid–prodrug nanoparticles
10.1038/s44222-023-00082-0 · doi-reference
Co-administration of iRGD enhances tumor-targeted delivery and anti-tumor effects of paclitaxel-loaded PLGA nanoparticles for colorectal cancer treatment
10.1201/9780429065767 · doi-reference
CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape
10.1016/j.ijpharm.2019.118518 · doi-reference
N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer
10.1016/j.jconrel.2018.03.013 · doi-reference
Design, synthesis, and antitumor activity of novel thioheterocyclic nucleoside derivatives by suppressing the c-MYC pathway
10.1016/j.apsb.2025.05.008 · doi-reference
Chemotherapeutic Spherical Nucleic Acids
10.1021/acsnano.5c16609 · doi-reference
Novel telomere-targeting dual-pharmacophore dinucleotide prodrugs for anticancer therapy
10.1093/nar/gkaf591 · doi-reference
Antibody–drug conjugates: recent advances in payloads
10.1016/j.apsb.2023.06.015 · doi-reference
Advancements in pH-responsive nanocarriers: enhancing drug delivery for tumor therapy
10.1080/17425247.2023.2292678 · doi-reference
Innovative nanomedicine delivery: targeting tumor microenvironment to defeat drug resistance
10.3390/pharmaceutics16121549 · doi-reference
Membrane‐permeable triphosphate prodrugs of nucleoside analogues
10.1002/anie.201511808 · doi-reference
Enhanced stability and efficacy of GEM-TOS prodrug by co-assembly with antimetastatic shell LMWH-TOS
10.1016/j.apsb.2019.06.008 · doi-reference
Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping
10.1002/cpt.2667 · doi-reference
1530P Patient derived organoids reveal synergy between NUC-7738 and PD-1 inhibition in renal cell carcer
10.1016/j.annonc.2025.08.2161 · doi-reference
455MO NUC-7738 in patients with advanced solid tumours: phase I results from the NuTide: 701 phase I/II study
10.1016/j.annonc.2022.07.584 · doi-reference
The novel nucleoside analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human phase I clinical trial
10.1158/1078-0432.ccr-21-1652 · doi-reference
A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide: 302)
10.1200/jco.2021.39.3_suppl.93 · doi-reference